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ABSTRACT
Background Countries around the world seek 
innovative ways of closing their remaining gaps towards 
the target of 95% of people living with HIV (PLHIV) 
knowing their status by 2030. Offering kits allowing HIV 
self- testing (HIVST) in private might help close these 
gaps.
Methods We analysed the cost, use and linkage 
to onward care of 11 HIVST kit distribution models 
alongside the Self- Testing AfRica Initiative’s distribution 
of 2.2 million HIVST kits in South Africa in 2018/2019. 
Outcomes were based on telephonic surveys of 4% of 
recipients; costs on a combination of micro- costing, 
time- and- motion and expenditure analysis. Costs were 
calculated from the provider perspective in 2019 US$, 
as incremental costs in integrated and full costs in 
standalone models.
Results HIV positivity among kit recipients was 
4%–23%, with most models achieving 5%–6%. Linkage 
to confirmatory testing and antiretroviral therapy (ART) 
initiation for those screening positive was 19%–78% and 
2%–72% across models. Average costs per HIVST kit 
distributed varied between $4.87 (sex worker model) and 
$18.07 (mobile integration model), with differences largely 
driven by kit volumes. HIVST kit costs (at $2.88 per kit) and 
personnel costs were the largest cost items throughout. 
Average costs per outcome increased along the care 
cascade, with the sex worker network model being the 
most cost- effective model across metrics used (cost per kit 
distributed/recipient screening positive/confirmed positive/
initiating ART). Cost per person confirmed positive for 
HIVST was higher than standard HIV testing.
Conclusion HIV self- test distribution models in 
South Africa varied widely along four characteristics: 
distribution volume, HIV positivity, linkage to care and 
cost. Volume was highest in models that targeted 
public spaces with high footfall (flexible community, 
fixed point and transport hub distribution), followed 
by workplace models. Transport hub, workplace and 
sex worker models distributed kits in the least costly 
way. Distribution via index cases at facility as well as 
sex worker network distribution identified the highest 
number of PLHIV at lowest cost.
INTRODUCTION
South Africa is the country with the most 
severe burden of HIV infections worldwide, 
with an estimated 7.8 million people living 
with HIV (PLHIV) and AIDS- related deaths 
that account for over 23% of all reported 
deaths in 2019.1 Further reductions of AIDS- 
related deaths and HIV transmission can be 
Key questions
What is already known?
 ► HIV self- testing (HIVST) is the latest addition to the 
growing list of HIV testing options for countries with 
a high HIV prevalence such as South Africa.
 ► Recent studies have shown it as a strategy that is 
acceptable, feasible and effective in maximising HIV 
testing uptake in other sub- Saharan African coun-
tries with high HIV prevalence.
 ► We collected data on the uptake, positivity, linkage to 
care and cost of 11 HIVST kit distribution strategies 
alongside the Self- Testing AfRica Initiative’s distribu-
tion of 2.2 million test kits in South Africa from mid-
2018 to mid-2019.
What are the new findings?
 ► We found that HIV self- test distribution models in 
South Africa varied widely along four characteristics: 
distribution volume, HIV positivity, linkage to care 
and cost.
 ► Average costs per HIVST kit distributed varied be-
tween $4.87 (sex worker model) and $18.07 (mobile 
integration model), with differences largely driven 
by kit volumes and level of integration into already 
existing services.
 ► HIVST kit costs (at $2.88 per kit) and personnel costs 
were the largest cost items throughout, but the sex 
worker network model was the most cost- effective 
model across all metrics used (cost per kit distrib-
uted/recipient screening positive/confirmed positive/
initiating antiretroviral therapy).
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facilitated by identifying PLHIV who are unaware of their 
HIV status, early diagnosis and engagement with antiret-
roviral therapy (ART).2 Although the last HIV household 
survey, in 2017, showed that 85% of all HIV- positive indi-
viduals aged between 15 and 64 years had already been 
diagnosed, gaps remain, for example, in reaching men, 
with just below 80% being diagnosed, compared with 
89% of their female counterparts.3 As such, the need to 
intensify HIV testing remains a critical step in achieving 
the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) target to diagnose 95% of PLHIV by 2030.4
The South African National Department of Health has, 
in recent years, developed and implemented an array 
of innovative HIV testing strategies, such as community- 
based approaches, to complement provider- initiated HIV 
testing services offered at healthcare facilities in order 
to expand HIV testing service (HTS). HIV self- testing 
(HIVST), a process in which a person collects their own 
specimen (blood or oral fluid), performs HIV testing 
using an HIV rapid diagnostic test, generally in private, 
and interprets the result themselves either assisted 
or unassisted,5 has become the latest addition to the 
growing list of HIV testing options, with recent studies 
having shown it as a strategy that is acceptable, feasible 
and effective in maximising HIV testing uptake.6–8 More 
importantly, HIVST offers a much needed alternative 
that allows men in particular to overcome socio- structural 
barriers associated with perceived stigmatisation of using 
a clinic, a possibly unwelcoming attitude by mostly female 
clinic staff and by other clients, and clinic access being 
restricted to normal working hours.9 A recent model 
analysis by our team showed that, based on preliminary 
cost data and effectiveness data from other settings, 
HIVST combined with home- based testing would have 
the greatest impact towards the UNAIDS 95 target of 
all 10 testing modalities analysed, increasing the frac-
tion of diagnosed PLHIV to 96.5% by 2030, and would 
be highly cost- effective compared with currently funded 
HIV interventions.10
In 2017, the second phase of the Unitaid- funded Self- 
Testing AfRica (STAR) Initiative began to conduct HIVST 
implementation research in Eswatini, Lesotho and South 
Africa through different models of distribution which 
include workplace- based distribution, facility- based 
distribution and community- based distribution. Over 3 
million HIVST kits were distributed between 2017 and 
2020 across all three countries. In South Africa, HIVST 
distribution was mainly targeted at men given their lower 
historical uptake of HIV testing services; previous analysis 
by our team showed that the workplace model in partic-
ular was effective in reaching men who had not been 
tested before, or not in the last 12 months.11 Previous 
work by our team evaluated the cost of community- 
based HIVST distribution through STAR to be, in 2019 
US$, between US$8.91 and US$9.66 per kit distributed 
in Malawi, US$17.70 in Zambia, US$14.91 in Zimbabwe 
and US$14.03 in Lesotho, comparable with the cost of 
standard HIV testing services in each country. These esti-
mates however did not take onward linkage and the cost 
of confirmatory testing for people screening positive with 
HIVST into account, making direct comparisons with 
existing.12–14 This study adds to this by presenting the cost 
and intermediary cost- effectiveness of distributing oral 
fluid- based HIVST and onward linkage to confirmatory 
testing and treatment services through 11 distribution 
models in South Africa in an effort to provide evidence 
for governments making decisions regarding the further 
scale up of self- testing after the end of the STAR initiative.
METHODS
Description of models
Our economic evaluation included the three main 
HIVST models: facility, community and workplace. Each 
model comprised of discrete distribution submodels that 
were defined as follows:
Facility distribution models
Horizontal primary healthcare (antenatal care)
As part of post- test counselling in routine HTS, women 
attending their first antenatal care (ANC) visit at a primary 
healthcare (PHC) clinic were offered HIVST kits, to take 
home to their current male sexual partner(s)—defined as 
secondary distribution. This excluded pregnant women 
whose sexual partners had been diagnosed HIV positive 
or had tested HIV negative within the previous 3 months.
Horizontal PHC (index)
HIVST kits were offered by existing PHC staff to newly 
diagnosed and previously known HIV- positive clients at a 
PHC clinic to share with their sexual partner(s) or family 
members who were unaware of their HIV status.
Vertical PHC
This model involved primary distribution of HIVST 
for on- site screening of clients attending the clinic for 
different services including family planning and treat-
ment for sexually transmitted infections. This model also 
used distribution agents employed by implementing part-
ners to distribute kits in the clinics, as opposed to trained 
lay counsellors already employed by the clinic in the hori-
zontal models.
Key questions
What do the new findings imply?
 ► Policymakers making decisions about whether to add HIVST to the 
HIV testing strategies can use our findings to decide between mod-
els that allow large numbers of kits to be distributed quickly (mod-
els that target public spaces with high footfall, such as community 
and transport hub distribution models, or workplace models), those 
that distribute kits in the least costly way (transport hub, workplace 
and sex worker models), or those that identify the highest number 
of people living with HIV at lowest cost (distribution via index cases 
at facility as well as sex worker network distribution).Across mod-
els, we however found that the cost per person confirmed positive 
through HIVST was higher than that of standard HIV testing.




HIVST kits were distributed at preselected locations 
within local communities. Distribution agents set up 
testing tents near areas where men tend to congre-
gate (such as hostels, taverns and brothels), provided a 
demonstration of HIVST kit use to a group or individ-
uals through either video or physical demonstration, 
and distributed HIVST kits to consenting clients. Clients 
who chose to take up HIVST were given an option of self- 
testing in one of the small tents on- site or taking the kit 
home for their private use. For clients screening positive 
on site, confirmatory testing conducted by a professional 
provider was offered on- site.
Mobile integration
This model involved integrating HIVST distribution 
into community- based mobile HTS in mobile testing 
units. In comparison with facility- based services, mobile 
testing units are more likely to reach men.15 Similar to 
fixed- point distribution, clients were given the opportu-
nity to screen on- site, and in the case of a reactive self- 
test, attend confirmatory testing in the mobile testing 
unit.
Transport hub
This model involved the distribution of HIVST kits to 
commuters, taxi drivers and street vendors in densely 
populated taxi ranks and train stations, with high foot 
traffic. Distribution agents provided a demonstration of 
HIVST kit use and offered kits to interested clients for 
private use off- site.
Key populations
HIVST kits were offered to sex workers and truck drivers 
across four provinces of Free State, Gauteng, KwaZulu 
Natal and Mpumalanga. This was largely not part of an 
established key populations programme and involved 
visiting key populations’ hot spots such as bars, brothels, 
borders and truckers’ resting spots among other distri-
bution points. Kits were for recipients’ own use, either 
on- site or off- site.
Sex workers
As part of an established sex worker health programme, 
HIVST kits were offered to consenting sex workers to 
distribute to peers who they thought might be at risk of 
HIV and not yet tested and who might or not be engaged 
in sex work themselves. Kits were not distributed to clients 
or for use by the sex workers themselves, and were only 
given to sex workers who were aware of their own status.
Flexible community model
The flexible community distribution model involved 
door- to- door kit distribution including distribution in 
marketplaces, hot spots, malls, community events and 
informal workplaces in communities as well as distribu-
tion as part of promoting voluntary medical male circum-
cision uptake. The targeted population were men and 
young people; kits were for their own use or to distribute 
to a sexual partner or partners.
Workplace distribution models
Workplace distribution was predominantly conducted 
in a number of male- dominated sectors such as manu-
facturing, mining, construction, security, petroleum and 
agriculture. There were two types of workplaces included: 
(a) larger companies that did not have formalised HIV 
testing programmes or had a significantly low HIV testing 
uptake were contacted before the distribution event for 
sensitisation; (b) distribution also took place more ad 
hoc and without prior arrangement with management to 
employees of smaller workplaces such as petrol stations 
or construction sites. We distinguished between a work-
place (third- party) and a workplace (direct) distribution 
model, based on whether a third- party implementing 
organisation or a direct STAR partner was used to 
conduct the distribution.
Survey outcomes and data analysis
Distribution agents collected demographic information 
(year of birth, sex) of recipients of primary and, where 
relevant, secondary distribution using paper- based data 
collection forms or electronic tablets. Primary recipients 
consenting to telephonic follow- up calls provided their 
cellular phone number. A subset of consenting recipi-
ents was followed up telephonically with up to three calls 
at approximately 2- week, 4- week and 6- week time inter-
vals post- distribution, following convenience sampling. 
During the call, a trained linkage officer administered 
a standardised questionnaire to record kit usage by 
the primary recipient and/or their partners as well as 
the HIVST result and, in the case of a positive result, 
whether recipients had attended confirmatory testing 
and initiated ART. For the mobile integration model 
only, outcomes data included recipients screening on- site 
only; linkage to care was established by record review in 
surrounding clinics through local HIV care organisa-
tions rather than telephonic interview. We calculated the 
percentages of kits whose recipients (a) were success-
fully called and stated that they or their partner had (b) 
used the kit, and for those screening positive for HIV, 
stated that they or their partner had linked to care for 
(c) confirmatory testing and (d) ART initiation. We then 
applied these percentages to the total number of kits 
distributed to estimate uptake, HIV screening positivity 
and linkage rates for the entire population of self- test kit 
recipients, allowing us to produce model- specific care 
cascades. Survey data were entered into Excel databases 
summarised by model. Statistical analysis was performed 
using SAS Enterprise Guide V.5.1 (Statistical Analysis 
Software Institute).
Cost analysis
In accordance to international costing guidelines 
adopted from the Global Health Cost Consortium refer-
ence case16 and using the same methods used in phase 
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1 of the STAR initiative, the cost analysis was conducted 
in order to provide comparable results across all coun-
tries covered by the STAR initiative.13 In short, economic 
costs were estimated from the provider perspective and 
included capital cost items such as start- up training, 
sensitisation and equipment, and recurrent cost items 
such as personnel, test kits, other supplies, transporta-
tion, and building operation and maintenance. Capital 
costs were annualised over the 2 years’ duration of the 
initiative’s work in South Africa, using a 3% discount 
rate. Since most costs were recorded in expenditure logs 
maintained by the implementing partners, we used a 
detailed expenditure analysis complemented by activity- 
based observations (time- and- motion analysis) and 
micro- costing, in particular of those models that shared 
resources with existing activities—the facility and mobile 
integration models. For these two models, incremental 
costs were estimated, while costs for the other models 
represented the full costs of implementation. Costs were 
estimated in 2018/2019 South African rand (ZAR) and 
converted to US dollars (US$) using the period average 
of 14 ZAR=US$1.17
We allocated resources shared across a number of 
models, such as the time of management and supervision 
staff as well as vehicles and distribution equipment based 
on expenditure codes that implementing staff had been 
trained to add to each payment requisition and invoice 
over the course of the project. In addition, detailed, 
repeated interviews with team managers over the dura-
tion of the project were conducted to fill in gaps left by 
the expenditure coding and add clarification.
We combined these data with micro- costing data to esti-
mate the total cost of each model over 12 months of imple-
mentation (including capital costs that had been incurred 
before this 12- month period), and divided total costs by the 
number of HIVST kits distributed in each model during the 
same time period to arrive at average costs per kit distrib-
uted. Data collection time periods varied slightly between 
models: the workplace and transport hub models were 
implemented in two shorter time periods in March 2018–
September 2018 and September 2019, and in July 2018–
March 2019 and August–September 2019, respectively, 
which were the time periods included in the analysis. For 
all other models, we used resource use and outcomes 12 
consecutive months: July 2018–June 2019 for the flexible 
community, key populations, workplace and vertical PHC 
models, and April 2018–March 2019 for all remaining 
models. While we included all start- up and preparation 
costs regardless of when they were accrued, our analysis of 
recurrent costs was restricted to time periods of full imple-
mentation, in order to include a more representative set of 
operations at full efficiency.
Our analysis assumed a unit price of $2 per kit following 
a charitable support agreement between the Bill and 
Melinda Gates Foundation and the OraSure Technologies 
Incorporated (OraQuick HIV Self- test manufacturer).18 
A marginal freight and shipping cost from the manufac-
turer to central warehouses in South Africa was estimated 
to be $0.88 based on central expenditure records from 
Population Sciences International, a non- profit organi-
sation that was mandated to distribute HIVST kits under 
STAR. Total costs, average cost per test kit distributed and 
average cost per client initiated on ART were estimated 
and summarised by model.
Intermediary cost-effectiveness analysis
We combined the cost and outcomes data to estimate the 
cost of HIVST distribution per person screening positive 
with a kit, per person found HIV positive in confirmatory 
testing and per person initiating ART. We added the cost of 
facility- based confirmatory testing with rapid tests based on 
an update to a previous analysis10 to the latter two cost esti-
mates, and the cost of an ART initiation visit without addi-
tional testing the cost estimate per person initiating ART.19
Patient and public involvement
Patients or the public were not involved in the design, 
recruitment, conduct or dissemination of this study.
RESULTS
Outcomes
During the 12- month costing period (mid-2018 to 
mid-2019), a total of 1 111 726 HIVST kits were distrib-
uted across the models, with 49% distributed through the 
flexible community model, and another 19% distributed 
through the workplace (third- party) model. The least 
number of HIVST kits, less than 1% each, were distrib-
uted through the mobile integration, horizontal PHC 
and vertical PHC models (online supplemental table S1).
Telephonic follow- up aimed at a response rate of at 
least 10% of all recipients but varied significantly across 
models, with a total of 52 195 clients called, and 40 834 
clients reached (5% and 4% of recipients, respectively). 
Models with the highest percentage of recipients reached 
were the horizontal PHC models (ANC, 64% and index, 
77%) (online supplemental table S1). The high follow- up 
in these facility models was intended and was facilitated 
by low HIVST kit distribution volumes in these models. 
Conversely, follow- up for higher volume models such as 
the transport hubs, sex worker network and workplace 
(third- party) models ranged from 3% to 30%.
HIV screening positivity ranged between 4% in the 
third- party workplace model and 23% in the horizontal 
PHC (index) model (figure 1 and online supplemental 
table S1). The majority of models had around 5% posi-
tivity. The proportion of recipients screening positive with 
an HIVST kit who reported to have obtained confirma-
tory testing ranged from 19% in the sex worker network 
model to 78% in the horizontal PHC (ANC) model 
(figure 1). Out of those clients with reactive HIVST who 
obtained confirmatory testing, between 4% (fixed point 
model) and 100% (vertical PHC model) reported to have 
initiated ART. This means that out of everyone screening 
positive, between 2% (fixed- point model) and 72% (hori-
zontal PHV model, ANC) initiated ART.
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Distribution costs
The total cost of HIVST kit distribution varied signif-
icantly across models, ranging from $39 276 in the 
mobile integration model to $4 003 412 in the flexible 
community model (table 1). The average cost per HIVST 
kit distributed varied between $4.87 in the sex worker 
model and $18.07 in the mobile integration model, with 
distributed kit volumes driving most of the difference 
in average costs, suggesting strong economies of scale 
(figure 2). Facility- based models exhibited higher average 
cost per HIVST kit distributed compared with almost all 
community- based and workplace- based models, with the 
exception of the mobile integration model (figure 2).
Recurrent costs accounted for 75% or more of total costs 
in all models except the key populations model (62%) 
(online supplemental figure S1). Personnel and HIVST 
kit costs were key cost drivers across all models (online 
supplemental figure S1). Personnel costs accounted for 
more than 50% of the total cost of distribution across all 
PHC models, and to less than 10% in the key populations 
and direct workplace model. Although the unit price of 
an HIVST test kit before shipping remained constant 
at $2.00 throughout the costing period, the total cost 
contribution of HIVST kits varied significantly across 
all models, accounting for a range between 13% in the 
vertical PHC model and 67% in the workplace (direct) 
model (table 1).
Intermediary cost-effectiveness
When taking into account cost per intermediary outcome 
such as the number of recipients screening positive, 
confirmed positive and initiating ART, two trends were 
apparent.
First, cost per outcome increased by one to three 
orders of magnitude as a result of the inclusion of 
additional items such as confirmatory testing and ART 
initiation at a heath facility (figure 3). This increment 
in magnitude was especially influenced by the much 
smaller denominator defined by the HIV screening 
positivity, particularly in the vertical PHC, mobile 
integration, key populations and workplace (direct) 
models (online supplemental table S2). The cost 
per recipient screening positive ranged from $28 in 
the sex worker model to $382 in the mobile integra-
tion model; the cost per recipient confirmed positive 
ranged from $59 in the sex worker model to $1229 
in the vertical PHC model; and the cost per recipient 
initiating on ART ranged from $112 in the sex worker 
model to $5164 in the fixed point model (online 
supplemental table S2). Two community models, the 
fixed point and the mobile integration models, had 
particularly steep increases between the cost per recip-
ient confirmed positive and initiating on ART due to 
the large drop- offs between these two levels of care.
Second, the ranking of models from least to most costly 
per outcome was steered by the differences between 
models in both HIV positivity and onward linkage to care 
(table 2). Among the facility models (blue in table 2), 
the horizontal models were both cheaper and more 
cost- effective than the vertical model which employed 
stand- alone distribution staff, with the horizontal index 
testing model being the cheapest and most cost- effective 
facility option—in fact, the second most effective option 
of all 11 models, after the sex worker model, and across 
all outcome metrics. Among the workplace models, the 
Figure 1 Care cascades by model. *Outcomes data on the mobile integration model included recipients screening on- site 
only; linkage to care was established by record review rather than telephonic interview, possibly biasing results downwards. 
ANC, antenatal care; ART, antiretroviral therapy; PHC, primary healthcare.
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direct model was more cost- effective throughout than the 
model implemented by a third party, even though the 
former distributed more test kits.
DISCUSSION
Our analysis summarises the cost, HIV screening posi-
tivity and linkage outcomes of a wide range of HIVST 
distribution mechanisms in South Africa, representing 
almost all models currently in use in the country. These 
include facility- based and community- based models as 
well as workplace models, primary and secondary distri-
bution, and integrated as well as standalone models. The 
analysis thus serves as a good evidence base on which to 
base decisions regarding which models should be scaled 
up further, and how to improve the cost- effectiveness of 
existing models.
The way that models rank based on different outcome 
metrics has implications for decision- making. If the aim 
is to identify the model to distribute the largest number 
of kits through, the choice would be the workplace and 
community models aimed at the general population, 
such as the flexible community, transport hub or fixed- 
point models, while the facility and sex worker/key 
population models would be less attractive. (Here it is 
important to bear in mind that kit volumes distributed 
in this study were subject not only to demand but also 
to a number of supply side factors, including capacity 
and convenience, which might play out differently in 
Figure 2 Relationship between distributed kit volumes by model, average cost per distributed kit and positivity (bubble size). 
Facility models are marked blue, community models, teal, and workplace models, orange. ANC, antenatal care; PHC, primary 
healthcare.
Figure 3 Cost per outcome by model. ANC, antenatal care; ART, antiretroviral therapy; PHC, primary healthcare.
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routine implementation; additionally, there might be a 
demand saturation effect if the same venues were to be 
used regularly.20) If the aim is to distribute kits most effi-
ciently and least costly, the transport hubs and workplace 
models would still be attractive, but so would be the sex 
worker model. If however the aim is to distribute kits in a 
way that finds the most HIV- positive people most cheaply, 
then secondary distribution via index cases at facility as 
well as integration into existing sex worker programmes 
and distribution to their networks is the most efficient 
choice. The large- volume models (workplace, transport 
hub or fixed- point models) achieve greater demand, 
largely due to the bigger footfall in busy urban thorough-
fares and distribution to ‘captive audiences’ at urban and 
rural workplaces, but do so at the cost of smaller HIV 
positivity—in some cases augmented by lower linkage 
to onward care—and might be the first to saturate. The 
cost- effectiveness of these models might be augmented 
by improved targeting of population groups at higher 
risk of HIV acquisition.
Overall, the costs of HIVST distribution that we found 
across models in this study are comparable with those 
of community- based HIVST distribution estimated by 
our team, between $8.91 and $17.70 in Malawi, Zambia, 
Zimbabwe and Lesotho.12–14 We found that the costs are 
lower the more flexible and nimble the model is, such 
as all community models, and lower in models that inte-
grate into existing services, such as in the sex worker 
model or the horizontal PHC models. Models that had 
milestone- based contracts, such as the third- party work-
place and transport hub models, also achieved higher 
volumes more cheaply than those where this was not a 
possibility. Compared with the cost per positive HIV test 
from our previous analysis, which ranged from $4.74 
(home- based testing in an urban setting) to $17.89 
(mobile testing with mobilisation event) in 2016 US$,10 
our cost per person confirmed positive ($59–$1229) is 
much more expensive—pointing to the fact that iden-
tifying PLHIV will only ever get more expensive, given 
dwindling yield and the need for innovative methods to 
reach those reluctant to test.
Our study’s findings stand next to a number of limita-
tions. First, implementation was managed by a non- 
governmental initiative, and both costs and outcomes 
might change once HIVST becomes part of routine care. 
Outcomes depending on HIV positivity, in particular, 
which, if HIV testing coverage keep up with the epidemic, 
will decrease over time as more PLHIV know their status, 
and the identification of new PLHIV will mostly be driven 
by HIV incidence. Second, our outcomes were based on 
telephonic surveys of recipients and are thus subject 
to a number of biases, including differential consent 
to being surveyed and response rates between models. 
Another aspect is the potential for social desirability bias 
in responding to survey questions which might have led 
people to respond positively to the question whether 
they had used the HIVST kit or linked to onward care, 
and possibly in the negative to the question what the test 
result was if they had not in fact used the kit. While this 
would have led to an overestimation of uptake and an 
underestimation of true screening positivity, these biases 
are less likely to differ by model in such a way and magni-
tude that our recommendations no longer hold. Third, 
we did not differentiate between primary and secondary 
distribution, given that all models with the exception of 
the sex worker and the horizontal PHC models used both 
methods, and recommendations for one over the other 
would ignore that there is often demand for both and 
Table 2 Ranking of models by outcome
Number of kits 
distributed 
(decreasing)
Cost per test kit 
distributed (increasing)
Cost per recipient 
screening positive 
(increasing)
Cost per recipient 
confirmed positive 
(increasing)
Cost per recipient 
initiating ART 
(increasing)
Flexible community Sex worker Sex worker Sex worker Sex worker
Workplace (Third 
party)
Transport hubs Horizontal PHC (Index) Horizontal PHC (Index) Horizontal PHC (Index)
Transport hubs Workplace (Direct) Transport hubs Transport hubs Transport hubs
Fixed point Key populations Workplace (Direct) Fixed point Workplace (Direct)
Workplace (Direct) Flexible community Fixed point Workplace (Direct) Horizontal PHC (ANC)
Key populations Workplace (Third party) Workplace (Third party) Workplace (Third party) Workplace (Third party)
Sex worker Fixed point Horizontal PHC (ANC) Horizontal PHC (ANC) Mobile integration
Vertical PHC Horizontal PHC (Index) Mobile integration Mobile integration Fixed point
Horizontal PHC 
(ANC)
Horizontal PHC (ANC) Vertical PHC Vertical PHC Flexible community
Horizontal PHC 
(Index)
Mobile integration Flexible community Flexible community Vertical PHC
Mobile integration Vertical PHC Key populations Key populations Key populations
Facility models are marked in different shades of blue, community models, in teal, and workplace models, in orange. (Note that the depth of 
shade has no significance other than to make it easier to identify and compare the position of each individual model across the rubrics).
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the most efficient models seem to be those that fulfil this 
demand flexibly, adding kits to take to partners to every 
distribution of kits for the recipient’s own use. Further 
details of these differences can be found in Sande et 
al (submitted to the same issue). Lastly, our analysis 
stopped at intermediary outcomes particular to HIVST; 
a full comparison with other HIV testing modalities on 
the one hand and other HIV interventions on the other 
would require the inclusion of modelled outcomes such 
as life- years saved and HIV infections averted as well as 
the consideration of the full cost of the national HIV 
programme, including antiretroviral treatment, which 
was not part of this analysis. Our recommendations, 
while useful for choosing between channels for HIVST 
distribution once a decision for HIVST scale- up has been 
made, do hence not help with the decision of whether or 
not HIVST should in fact be funded and further scaled 
up from a limited public HIV budget.
CONCLUSION
HIV self- test distribution models varied widely along 
four characteristics: distribution volume, screening posi-
tivity, linkage to onward HIV care and cost. Distribution 
volume was highest in models that flexibly distributed 
kits throughout different public spaces and hot spots in a 
community (flexible community model) or that targeted 
public spaces with high footfall (fixed- point and trans-
port hub distribution), followed by the workplace model 
that used small, nimble teams and innovative manage-
ment strategies, and focused on easily accessible urban 
workplaces such as filling stations and restaurants on the 
same site, as well as large urban and rural workplaces. 
Screening positivity was highest in the models targeting 
sex worker networks and partners of known HIV posi-
tives (index testing). Linkage to confirmatory testing was 
highest in the models that offered testing on- site, while 
ART initiation among HIVST users screening positive 
was highest in models that were situated within a facility. 
The lowest rates of confirmatory testing and ART initia-
tion were seen in the standalone key populations model, 
possibly owing to the transitory nature of the audience 
which might have made it harder to direct recipients to 
the relevant closest clinics should they need further care.
Adding cost and comparing cost with these different 
outcome metrics, we were able to identify different 
options depending on decision makers’ priorities: the 
sex worker and transport hubs models as well as one of 
the workplace models distribute kits in the most efficient 
and least costly way. If however the aim is to distribute 
kits in a way that finds the most HIV- positive people most 
cheaply, then secondary distribution via index cases at 
facility as well as sex worker network distribution are the 
most efficient choices.
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